Delayed Application of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer
brief summary
This study is a multicenter, randomized, open-label phase 3 trial of delayed administration of immunotherapy in patients who are planned to receive chemoimmunotherapy for newly diagnosed, advanced or metastatic, PD-L1 positive NSCLC without sensitizing alterations in EGFR, ALK, or ROS1.
detailed description
This study enrolls patients with newly diagnosed, PD-L1 positive (PD-L1 TPS ≥ 1%), EGFR/ALK/ROS1-wildtype/-negative, advanced or metastatic non-small cell lung cancer who have not yet received systemic treatment.
Patients are randomized into two treatment arms. In both arms, patients receive standard treatment with histology-guided chemotherapy in combination with the PD-1 inhibitor cemiplimab. Patients in the experimental arm receive chemotherapy on Day 1 and cemiplimab on Day 4 of each cycle. Patients in the control arm receive both therapies on Day 1 of each cycle. After 4 cycles, patients continue with cemiplimab either with or without pemetrexed as per standard of care.
The time interval between chemotherapy and immunotherapy is intended to minimize antagonistic effects of chemotherapy on immunotherapy while simultaneously enhancing potential synergistic effects between the two treatment modalities.
official title
Delayed Application of Immune Checkpoint Inhibitors in Patients With Advanced or Metastatic NSCLC Receiving Chemoimmunotherapy